AC Immune signs $2.1B immunotherapy deal with Takeda Pharma to slow progression of Alzheimer’s disease

Exclusive option and licensing agreement for amyloid-beta active immunotherapy for Alzheimer’s disease

Japan-based pharmaceutical company Takeda and Swiss company AC Immune SA announce plans for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease Exclusive global selection and licensing agreement reached.

ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic form of Abeta, which is thought to promote plaque formation and Alzheimer’s disease progression. By inducing plaque clearance and effectively inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow the progression of Alzheimer’s disease. ACI-24.060 Study in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to evaluate the safety of an investigational immunotherapy in subjects with prodromal Alzheimer’s disease and adults with Down syndrome , tolerability, immunogenicity and pharmacodynamic effects syndrome.

Under the terms of the agreement, AC Immune will receive an upfront payment of $100 million and will be eligible to receive option exercise fees and additional potential development, commercial and sales milestones if all relevant milestones are exceeded over the course of the agreement. Upon commercialization, AC Immune will be entitled to double-digit tiered royalties on global net sales.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top